Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Bladder Cancer

  Free Subscription

Articles published in Urol Int

Retrieve available abstracts of 61 articles:
HTML format

Single Articles

    July 2020
  1. CHEN G, Yang T, Shao Q, Zhang M, et al
    Sub-Staging-Specific Differences in Recurrence-Free, Progression-Free, and Cancer-Specific Survival for Patients with T1 Bladder Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2020 Jul 1:1-7. doi: 10.1159/000506238.
    PubMed     Abstract available

    June 2020
  2. WU J, Wang YC, Luo WJ, Dai B, et al
    Diagnostic Performance of Confocal Laser Endomicroscopy for the Detection of Bladder Cancer: Systematic Review and Meta-Analysis.
    Urol Int. 2020 Jun 18:1-10. doi: 10.1159/000508417.
    PubMed     Abstract available

  3. NAKANE K, Enomoto T, Hishida S, Tomioka M, et al
    The Utility and Efficacy of Laparoscopic Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer at a Single Institution.
    Urol Int. 2020 Jun 17:1-7. doi: 10.1159/000508192.
    PubMed     Abstract available

  4. BUSETTO GM, Porreca A, Del Giudice F, Maggi M, et al
    SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?
    Urol Int. 2020 Jun 9:1-13. doi: 10.1159/000509065.
    PubMed     Abstract available

    May 2020
  5. XU J, Wang C, Ouyang J, Sun J, et al
    Efficacy and Safety of Transurethral Laser Surgery Versus Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis and Systematic Review.
    Urol Int. 2020 May 27:1-14. doi: 10.1159/000506655.
    PubMed     Abstract available

  6. SERRETTA V, Di Maida F, Baiamonte D, Vella M, et al
    Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study.
    Urol Int. 2020 May 5:1-6. doi: 10.1159/000507122.
    PubMed     Abstract available

    March 2020
  7. SUAREZ-IBARROLA R, Hein S, Farin E, Waldbillig F, et al
    Current Standards in the Endoscopic Management of Bladder Cancer: A Survey Evaluation among Urologists in German-Speaking Countries.
    Urol Int. 2020 Mar 25:1-7. doi: 10.1159/000506653.
    PubMed     Abstract available

    January 2020
  8. YANG H, Lin J, Gao P, He Z, et al
    Is the En Bloc Transurethral Resection More Effective than Conventional Transurethral Resection for Non-Muscle-Invasive Bladder Cancer? A Systematic Review and Meta-Analysis.
    Urol Int. 2020 Jan 7:1-8. doi: 10.1159/000503734.
    PubMed     Abstract available

    December 2019
  9. ZIEGELMUELLER BK, Jokisch JF, Buchner A, Grimm T, et al
    Long-Term Follow-Up and Oncological Outcome of Patients Undergoing Radical Cystectomy for Bladder Cancer following an Enhanced Recovery after Surgery (ERAS) Protocol: Results of a Large Randomized, Prospective, Single-Center Study.
    Urol Int. 2019 Dec 4:1-7. doi: 10.1159/000504236.
    PubMed     Abstract available

    October 2019
  10. FROEHNER M, Muallah D, Koch R, Hubler M, et al
    Socioeconomic Status-Related Parameters as Predictors of Competing (Non-Bladder Cancer) Mortality after Radical Cystectomy.
    Urol Int. 2019 Oct 22:1-8. doi: 10.1159/000502781.
    PubMed     Abstract available

    September 2019
  11. HAUTMANN RE, Bolenz C, Volkmer B
    Unexpected Early Oncologic Mortality after Open Radical Cystectomy for Bladder Cancer: Who Is to Be Blamed?
    Urol Int. 2019 Sep 27:1-6. doi: 10.1159/000503398.
    PubMed     Abstract available

    August 2019
  12. YOO SH, Kim H, Kwak C, Kim HH, et al
    Late Recurrence of Bladder Cancer following Radical Cystectomy: Characteristics and Outcomes.
    Urol Int. 2019 Aug 28:1-6. doi: 10.1159/000502656.
    PubMed     Abstract available

  13. CARANDO R, Zazzara M, Cotrufo S, Ludovico GM, et al
    Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study.
    Urol Int. 2019 Aug 28:1-6. doi: 10.1159/000502663.
    PubMed     Abstract available

    June 2019
  14. BI H, Huang Y, Wang G, Ma L, et al
    Impact of Body Mass Index and Pretreatment Hemoglobin Level on Prognosis Following Radical Cystectomy for Bladder Cancer in Males and Females.
    Urol Int. 2019 Jun 18:1-8. doi: 10.1159/000500561.
    PubMed     Abstract available

    March 2019
  15. CARRION A, Diaz F, Raventos C, Lozano F, et al
    Comparison of Outcomes between Standard and Palliative Management for High Grade Non-Muscle Invasive Bladder Cancer in Patients Older than 85 Years.
    Urol Int. 2019 Mar 7:1-7. doi: 10.1159/000496802.
    PubMed     Abstract available

    January 2019
  16. GROEBEN C, Koch R, Baunacke M, Borkowetz A, et al
    In-Hospital Outcomes after Radical Cystectomy for Bladder Cancer: Comparing National Trends in the United States and Germany from 2006 to 2014.
    Urol Int. 2019 Jan 30:1-9. doi: 10.1159/000496347.
    PubMed     Abstract available

  17. MOSCHINI M, Zamboni S, Mattei A, Baumeister P, et al
    Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?
    Urol Int. 2019 Jan 29:1-8. doi: 10.1159/000493899.
    PubMed     Abstract available

  18. ZIESCHANG H, Koch R, Wirth MP, Froehner M, et al
    Leiomyosarcoma of the Urinary Bladder in Adult Patients: A Systematic Review of the Literature and Meta-Analysis.
    Urol Int. 2019;102:96-101.
    PubMed     Abstract available

  19. LI A, Zhang P, Zhang M, Yang T, et al
    Transurethral Enucleation of Bladder Leiomyoma: A Series of Six Cases and Review of the Literature.
    Urol Int. 2019;102:102-108.
    PubMed     Abstract available

  20. SHIGEMURA K, Tanaka K, Hamasuna R, Ishikawa K, et al
    Efficacy of Prophylactic Antimicrobial Administration of Tazobactam/Piperacillin for Radical Cystectomy with Urinary Diversion: A Multicenter Study.
    Urol Int. 2019;102:293-298.
    PubMed     Abstract available

  21. URBINA-LIMA AD, Roman-Martin AA, Crespo-Santos A, Martinez-Rodriguez A, et al
    Solitary Fibrous Tumor of the Urinary Bladder Associated with Hypoglycemia: An Unusual Case of Doege-Potter Syndrome.
    Urol Int. 2019;103:120-124.
    PubMed     Abstract available

  22. SCHULZ GB, Grimm T, Buchner A, Kretschmer A, et al
    Benefits and Complications during the Stay at an Early Rehabilitation Facility after Radical Cystectomy and Orthotopic Ileum Neobladder Reconstruction.
    Urol Int. 2019;103:350-356.
    PubMed     Abstract available

  23. AZNAR MARTINEZ L, Lopez Cubillana P, Lopez Abad A, Vidal Crespo N, et al
    Bacillus Calmette-Guerin in Immunosuppressed Patient with High-Grade Nonmuscle Invasive Bladder Carcinoma.
    Urol Int. 2019;103:242-244.
    PubMed     Abstract available

    November 2018
  24. SANGUEDOLCE F, Russo D, Mancini V, Selvaggio O, et al
    Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review.
    Urol Int. 2018 Nov 21:1-13. doi: 10.1159/000494359.
    PubMed     Abstract available

  25. LAUSENMEYER EM, Braun K, Breyer J, Gierth M, et al
    Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer.
    Urol Int. 2018 Nov 1:1-6. doi: 10.1159/000493577.
    PubMed     Abstract available

    September 2018
  26. BOSSCHIETER J, Nieuwenhuijzen JA, Hentschel A, Vis AN, et al
    Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial.
    Urol Int. 2018 Sep 28:1-8. doi: 10.1159/000493159.
    PubMed     Abstract available

  27. KRAJEWSKI W, Zdrojowy R, Dembowski J, Poletajew S, et al
    The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
    Urol Int. 2018 Sep 28:1-9. doi: 10.1159/000491642.
    PubMed     Abstract available

  28. VETTERLEIN MW, Gild P, Marks P, Roschinski J, et al
    Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation.
    Urol Int. 2018 Sep 20:1-8. doi: 10.1159/000493369.
    PubMed     Abstract available

  29. KRAJEWSKI W, Matuszewski M, Poletajew S, Grzegrzolka J, et al
    Are There Differences in Toxicity and Efficacy between Various Bacillus Calmette-Guerin Strains in Bladder Cancer Patients? Analysis of 844 Patients.
    Urol Int. 2018 Sep 18:1-8. doi: 10.1159/000492722.
    PubMed     Abstract available

    August 2018
  30. MARI A, D'Andrea D, Kimura S, Resch I, et al
    Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer.
    Urol Int. 2018;101:1-4.
    PubMed     Abstract available

    May 2018
  31. DRAEGER DL, Sievert KD, Hakenberg OW
    Psychosocial Distress in Bladder Cancer Stratified by Gender, Age, Treatment, and Tumour Stage.
    Urol Int. 2018 May 14:1-7. doi: 10.1159/000489502.
    PubMed     Abstract available

    March 2018
  32. CERRUTO MA, D'Elia C, Siracusano S, Saleh O, et al
    Health-Related Quality of Life after Radical Cystectomy for Bladder Cancer in Elderly Patients with Ileal Orthotopic Neobladder or Ileal Conduit: Results from a Multicentre Cross-Sectional Study Using Validated Questionnaires.
    Urol Int. 2018 Mar 7. pii: 000487644. doi: 10.1159/000487644.
    PubMed     Abstract available

  33. DOGAN S, Hennig M, Frank T, Struck JP, et al
    Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice.
    Urol Int. 2018 Mar 6. pii: 000487405. doi: 10.1159/000487405.
    PubMed     Abstract available

    January 2018
  34. ZUCCHI A, Costantini E
    "Nested Type" Bladder Cancer: Myth or Reality?
    Urol Int. 2018 Jan 17. pii: 000486533. doi: 10.1159/000486533.

  35. TAN P, Xie N, Yang L, Liu L, et al
    Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma Increased the Risk of Intravesical Recurrence.
    Urol Int. 2018;100:92-99.
    PubMed     Abstract available

  36. PALAZZETTI A, Bosio A, Dalmasso E, Destefanis P, et al
    De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study.
    Urol Int. 2018;100:185-192.
    PubMed     Abstract available

  37. NIEGISCH G, Nini A, Michalski R, Henn A, et al
    Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion.
    Urol Int. 2018;101:224-231.
    PubMed     Abstract available

  38. GONZALEZ-PEREZ L, Alvarez-Arguelles H, Ramos Gutierrez VJ, Hernandez SG, et al
    Bladder Fetal Rhabdomyoma Intermediate Type.
    Urol Int. 2018;101:240-244.
    PubMed     Abstract available

  39. SANGUEDOLCE F, Landriscina M, Ambrosi A, Tartaglia N, et al
    Bladder Metastases from Breast Cancer: Managing the Unexpected. A Systematic Review.
    Urol Int. 2018;101:125-131.
    PubMed     Abstract available

  40. FERRO M, Vartolomei MD, Cantiello F, Lucarelli G, et al
    High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
    Urol Int. 2018;101:7-15.
    PubMed     Abstract available

  41. BEN BAHRIA-SEDIKI I, Chebil M, Sampaio C, Martel-Frachet V, et al
    Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
    Urol Int. 2018;100:476-484.
    PubMed     Abstract available

  42. GIERTH M, Zeman F, Denzinger S, Vetterlein MW, et al
    Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study.
    Urol Int. 2018;101:16-24.
    PubMed     Abstract available

  43. TAE BS, Ku JH, Kwak C, Kim HH, et al
    Comparison of Renal Function after Radical Surgery for Upper Tract Urothelial Carcinoma versus Renal Cell Carcinoma: Propensity Score Matching.
    Urol Int. 2018;101:400-408.
    PubMed     Abstract available

  44. BO S, Donghao S, Guangqi K, Ye T, et al
    CC Chemokine Ligand 18 Promotes Cell Proliferation and Metastasis of Urothelial Carcinoma via Activating PI3K/mTOR Signaling in Patient with Renal Transplantation.
    Urol Int. 2018;101:450-458.
    PubMed     Abstract available

    December 2017
  45. ZATTONI F, Palumbo V, Giannarini G, Crestani A, et al
    Perioperative Outcomes and Early Survival in Octogenarians Who Underwent Radical Cystectomy for Bladder Cancer.
    Urol Int. 2017 Dec 7. pii: 000478990. doi: 10.1159/000478990.
    PubMed     Abstract available

    June 2017
  46. NAGAO K, Hara T, Nishijima J, Shimizu K, et al
    The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
    Urol Int. 2017 Jun 21. doi: 10.1159/000477912.
    PubMed     Abstract available

  47. POLETAJEW S, Zapala P, Radziszewski P
    Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
    Urol Int. 2017 Jun 10. doi: 10.1159/000477673.
    PubMed     Abstract available

    April 2017
  48. BALCI M, Tuncel A, Keten T, Guzel O, et al
    Comparison of Monopolar and Bipolar Transurethral Resection of Non-Muscle Invasive Bladder Cancer.
    Urol Int. 2017 Apr 6. doi: 10.1159/000467397.
    PubMed     Abstract available

    March 2017
  49. NAKAMURA Y, Yoshida S, Tanaka H, Inoue M, et al
    Potential Utility of Diffusion-Weighted Magnetic Resonance Imaging in Diagnosis of Residual Bladder Cancer before Second Transurethral Resection.
    Urol Int. 2017 Mar 1. doi: 10.1159/000456722.
    PubMed     Abstract available

    February 2017
  50. MOSCHINI M, Shariat SF, Freschi M, Soria F, et al
    Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer.
    Urol Int. 2017 Feb 1. doi: 10.1159/000454736.
    PubMed     Abstract available

    January 2017
  51. LONG X, Qi L, Zu X, Li Y, et al
    Prevention of Recurrent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: An Individualized Selection Strategy Based on Patient Risk Stratification Is Needed.
    Urol Int. 2017;98:312-319.
    PubMed     Abstract available

  52. WOLTERS M, Oelke M, Lutze B, Weingart M, et al
    Deep Surgical Site Infections after Open Radical Cystectomy and Urinary Diversion Significantly Increase Hospitalisation Time and Total Treatment Costs.
    Urol Int. 2017;98:268-273.
    PubMed     Abstract available

    December 2016
  53. BREYER J, Otto W, Wirtz RM, Wullich B, et al
    ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.
    Urol Int. 2016.
    PubMed     Abstract available

  54. D'ELIA C, Comploj E, Cerruto MA, Trenti E, et al
    90-Day Mortality after Radical Cystectomy for Bladder Cancer: Prognostic Factors in a Multicenter Case Series.
    Urol Int. 2016.
    PubMed     Abstract available

    January 2016
  55. SOORIAKUMARAN P, Chiocchia V, Dutton S, Pai A, et al
    Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients.
    Urol Int. 2016;96:83-90.
    PubMed     Abstract available

  56. SERRETTA V, Scalici Gesolfo C, Alonge V, Cicero G, et al
    Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?
    Urol Int. 2016;96:20-4.
    PubMed     Abstract available

  57. MARTINI T, Aziz A, Roghmann F, Rink M, et al
    Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study.
    Urol Int. 2016;96:57-64.
    PubMed     Abstract available

  58. MILLER K, Morant R, Stenzl A, Zuna I, et al
    A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transi
    Urol Int. 2016;96:5-13.
    PubMed     Abstract available

  59. TANAKA H, Yoshida S, Komai Y, Sakai Y, et al
    Clinical Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management.
    Urol Int. 2016;96:65-72.
    PubMed     Abstract available

  60. GAKIS G, Efstathiou JA, Daneshmand S, Keegan KA, et al
    Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma.
    Urol Int. 2016;97:134-41.
    PubMed     Abstract available

  61. D''AGOSTINO D, Racioppi M, Pugliese D, Ragonese M, et al
    Postoperative Quality of Life in Patients with Ileal Neobladder at Short-, Intermediate- and Long-Term Follow-Up.
    Urol Int. 2016;97:54-60.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.